Mukhopadhyay Suman, Vander Heiden Matthew G, McCormick Frank
National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA.
Nat Cancer. 2021 Mar;2(3):271-283. doi: 10.1038/s43018-021-00184-x. Epub 2021 Mar 24.
Our understanding of how the RAS protein family, and in particular mutant KRAS promote metabolic dysregulation in cancer cells has advanced significantly over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer, and elucidating the underlying mechanisms could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers.
在过去十年中，我们对RAS蛋白家族，尤其是突变型KRAS如何促进癌细胞代谢失调的理解有了显著进展。在本综述中，我们讨论了致癌性RAS在癌症中介导的代谢重编程，阐明其潜在机制可能转化为针对RAS驱动型癌症代谢弱点的新治疗机会。
